Lexicon Pharma opts to co-promote sotagliflozin in USA

2 August 2017

Texan biotech firm Lexicon Pharmaceuticals (Nasdaq: LXRX) says it has exercised its option under its collaboration and license agreement with French pharma major Sanofi (Euronext: SAN) to co-promote sotagliflozin, an investigational oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), for the treatment of type 1 diabetes in the USA.

The opt-in decision was based on positive data from three Phase III studies, inTandem1, inTandem2, and inTandem3 and is aligned to a planned regulatory filing with the US Food and Drug Administration.

Sanofi intends to file applications in the first half of 2018 for the European Union and US regulatory reviews of sotagliflozin for the treatment of type 1 diabetes, pending the full read out of Phase III data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK